On April 12, 2024, AEON Biopharma, Inc. closed the transaction. The company issued one senior secured convertible note in the principal amount of $10,000,000 for a gross proceeds $10,000,000 in its final tranche. The Convertible Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date of April 12, 2027, unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.85 USD | -3.51% | -10.47% | -46.53% |
Apr. 12 | AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd | CI |
Apr. 01 | Sector Update: Health Care Stocks Slide Late Afternoon | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
111,900 KRW | -1.15% | +0.99% | 930M | ||
3.85 USD | -3.51% | -10.47% | 145M | ||
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-46.53% | 145M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-9.16% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- AEON Stock
- News AEON Biopharma, Inc.
- AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd